AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
NEW YORK & SUZHOU, China--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeartâ€), a global clinical-stage biopharmaceutical company developing novel…